The news is directly about Amicus Therapeutics and its rating by Morgan Stanley. The Equal-Weight rating suggests that the stock is expected to perform in line with the market or other stocks in its sector. The maintained price target indicates that the analyst's valuation of the company has not changed. This is likely to have a neutral impact on the stock's price in the short term.